vs

Side-by-side financial comparison of CBAK Energy Technology, Inc. (CBAT) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $58.8M, roughly 1.2× CBAK Energy Technology, Inc.). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -12.5%, a 396.6% gap on every dollar of revenue. On growth, CBAK Energy Technology, Inc. posted the faster year-over-year revenue change (131.8% vs 21.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs -0.0%).

CBAK Energy Technology, Inc. is a global supplier of lithium-ion battery products including high-performance cells, modules and battery packs. It serves key segments such as electric vehicles, stationary energy storage systems and consumer electronics, with core operations in China and a worldwide customer base.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

CBAT vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.2× larger
RIGL
$69.8M
$58.8M
CBAT
Growing faster (revenue YoY)
CBAT
CBAT
+110.6% gap
CBAT
131.8%
21.2%
RIGL
Higher net margin
RIGL
RIGL
396.6% more per $
RIGL
384.0%
-12.5%
CBAT
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
-0.0%
CBAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CBAT
CBAT
RIGL
RIGL
Revenue
$58.8M
$69.8M
Net Profit
$-7.4M
$268.1M
Gross Margin
7.3%
91.5%
Operating Margin
-13.6%
33.2%
Net Margin
-12.5%
384.0%
Revenue YoY
131.8%
21.2%
Net Profit YoY
-63.6%
1769.2%
EPS (diluted)
$-0.08
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBAT
CBAT
RIGL
RIGL
Q4 25
$58.8M
$69.8M
Q3 25
$60.9M
$69.5M
Q2 25
$40.5M
$101.7M
Q1 25
$34.9M
$53.3M
Q4 24
$25.4M
$57.6M
Q3 24
$44.6M
$55.3M
Q2 24
$47.8M
$36.8M
Q1 24
$58.8M
$29.5M
Net Profit
CBAT
CBAT
RIGL
RIGL
Q4 25
$-7.4M
$268.1M
Q3 25
$2.7M
$27.9M
Q2 25
$-3.1M
$59.6M
Q1 25
$-1.6M
$11.4M
Q4 24
$-4.5M
$14.3M
Q3 24
$17.6K
$12.4M
Q2 24
$6.4M
$-1.0M
Q1 24
$9.8M
$-8.2M
Gross Margin
CBAT
CBAT
RIGL
RIGL
Q4 25
7.3%
91.5%
Q3 25
8.0%
93.2%
Q2 25
11.0%
95.6%
Q1 25
13.7%
91.7%
Q4 24
13.1%
89.9%
Q3 24
15.6%
85.5%
Q2 24
26.6%
92.4%
Q1 24
31.9%
93.1%
Operating Margin
CBAT
CBAT
RIGL
RIGL
Q4 25
-13.6%
33.2%
Q3 25
-6.6%
40.9%
Q2 25
-8.7%
60.1%
Q1 25
-8.2%
23.9%
Q4 24
-26.0%
28.9%
Q3 24
-1.9%
25.4%
Q2 24
12.4%
1.2%
Q1 24
17.4%
-23.6%
Net Margin
CBAT
CBAT
RIGL
RIGL
Q4 25
-12.5%
384.0%
Q3 25
4.4%
40.2%
Q2 25
-7.6%
58.6%
Q1 25
-4.5%
21.5%
Q4 24
-17.8%
24.9%
Q3 24
0.0%
22.5%
Q2 24
13.5%
-2.8%
Q1 24
16.7%
-27.9%
EPS (diluted)
CBAT
CBAT
RIGL
RIGL
Q4 25
$-0.08
$14.11
Q3 25
$0.03
$1.46
Q2 25
$-0.03
$3.28
Q1 25
$-0.02
$0.63
Q4 24
$-0.05
$0.82
Q3 24
$0.00
$0.70
Q2 24
$0.07
$-0.06
Q1 24
$0.11
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBAT
CBAT
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$8.3M
$155.0M
Total DebtLower is stronger
$4.1M
$52.5M
Stockholders' EquityBook value
$112.7M
$391.5M
Total Assets
$426.2M
$513.6M
Debt / EquityLower = less leverage
0.04×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBAT
CBAT
RIGL
RIGL
Q4 25
$8.3M
$155.0M
Q3 25
$10.5M
$137.1M
Q2 25
$45.7M
$108.4M
Q1 25
$9.6M
$77.1M
Q4 24
$11.0M
$77.3M
Q3 24
$24.2M
$61.1M
Q2 24
$44.1M
$49.1M
Q1 24
$23.8M
$49.5M
Total Debt
CBAT
CBAT
RIGL
RIGL
Q4 25
$4.1M
$52.5M
Q3 25
$4.8M
$60.0M
Q2 25
$4.9M
$60.0M
Q1 25
$4.1M
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
CBAT
CBAT
RIGL
RIGL
Q4 25
$112.7M
$391.5M
Q3 25
$121.4M
$117.6M
Q2 25
$118.2M
$81.9M
Q1 25
$120.8M
$18.6M
Q4 24
$121.7M
$3.3M
Q3 24
$131.2M
$-14.6M
Q2 24
$126.6M
$-29.9M
Q1 24
$120.9M
$-31.7M
Total Assets
CBAT
CBAT
RIGL
RIGL
Q4 25
$426.2M
$513.6M
Q3 25
$363.9M
$242.5M
Q2 25
$333.1M
$206.7M
Q1 25
$311.5M
$176.0M
Q4 24
$302.2M
$164.0M
Q3 24
$293.5M
$139.4M
Q2 24
$279.6M
$128.4M
Q1 24
$286.5M
$126.5M
Debt / Equity
CBAT
CBAT
RIGL
RIGL
Q4 25
0.04×
0.13×
Q3 25
0.04×
0.51×
Q2 25
0.04×
0.73×
Q1 25
0.03×
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBAT
CBAT
RIGL
RIGL
Operating Cash FlowLast quarter
$29.8M
$22.0M
Free Cash FlowOCF − Capex
$16.1M
FCF MarginFCF / Revenue
27.3%
Capex IntensityCapex / Revenue
23.4%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$3.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBAT
CBAT
RIGL
RIGL
Q4 25
$29.8M
$22.0M
Q3 25
$14.6M
$24.0M
Q2 25
$13.8M
$30.5M
Q1 25
$-9.6M
$-893.0K
Q4 24
$9.6M
$14.5M
Q3 24
$19.7M
$21.7M
Q2 24
$2.9M
$302.0K
Q1 24
$7.4M
$-5.0M
Free Cash Flow
CBAT
CBAT
RIGL
RIGL
Q4 25
$16.1M
Q3 25
$6.0M
Q2 25
$4.1M
Q1 25
$-22.3M
Q4 24
$3.9M
Q3 24
$16.5M
Q2 24
$2.5M
Q1 24
$-454.0K
FCF Margin
CBAT
CBAT
RIGL
RIGL
Q4 25
27.3%
Q3 25
9.9%
Q2 25
10.2%
Q1 25
-63.9%
Q4 24
15.5%
Q3 24
37.1%
Q2 24
5.2%
Q1 24
-0.8%
Capex Intensity
CBAT
CBAT
RIGL
RIGL
Q4 25
23.4%
Q3 25
14.1%
Q2 25
23.8%
Q1 25
36.3%
Q4 24
22.5%
Q3 24
7.0%
Q2 24
0.9%
Q1 24
13.4%
Cash Conversion
CBAT
CBAT
RIGL
RIGL
Q4 25
0.08×
Q3 25
5.51×
0.86×
Q2 25
0.51×
Q1 25
-0.08×
Q4 24
1.01×
Q3 24
1115.72×
1.75×
Q2 24
0.46×
Q1 24
0.76×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBAT
CBAT

Manufacturing Lithium Batteries$28.0M48%
Residential Energy Supply And Uninterruptable Supplies$17.8M30%
Light Electric Vehicles$12.9M22%
Precursor$108.0K0%

RIGL
RIGL

Segment breakdown not available.

Related Comparisons